Vericel Corp Files 8-K on Financials

Ticker: VCEL · Form: 8-K · Filed: Jan 14, 2025 · CIK: 887359

Sentiment: neutral

Topics: financial-reporting, sec-filing, operations

TL;DR

Vericel filed an 8-K on Jan 14, 2025, covering financial results and operations.

AI Summary

Vericel Corporation filed an 8-K on January 14, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company, formerly known as Aastrom Biosciences Inc., is incorporated in Michigan and headquartered in Cambridge, MA.

Why It Matters

This 8-K filing provides investors with crucial updates on Vericel Corporation's financial performance and operational status, enabling informed investment decisions.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.

Key Numbers

Key Players & Entities

FAQ

What specific financial information is being disclosed in this 8-K?

The 8-K indicates disclosure regarding 'Results of Operations and Financial Condition', 'Regulation FD Disclosure', and 'Financial Statements and Exhibits'.

When was the earliest event reported in this filing?

The earliest event reported is January 14, 2025.

What is Vericel Corporation's state of incorporation?

Vericel Corporation is incorporated in Michigan.

What is the company's principal executive office address?

The principal executive offices are located at 64 Sidney Street, Cambridge, MA 02139.

Was Vericel Corporation always known by this name?

No, the company was formerly known as Aastrom Biosciences Inc., with a date of name change on April 28, 1996.

Filing Stats: 929 words · 4 min read · ~3 pages · Grade level 11.6 · Accepted 2025-01-14 16:05:21

Filing Documents

02

Item 2.02. Results of Operations and Financial Condition. In connection with its participation in the 43 rd Annual J.P. Morgan Healthcare Conference, on January 14, 2025, Vericel Corporation (the "Company") issued a press release and updated its corporate presentation, both of which include estimates of operating and financial results as of and for the year ended December 31, 2024. The Company's corporate presentation includes additional updates regarding its business. Because the Company's financial statements for the year ended December 31, 2024, have not been finalized or audited, these preliminary statements regarding the Company's operating and financial results as of and for the year ended December 31, 2024, are subject to change and the Company's actual results as of the end of this period may differ materially from this preliminary estimate. Accordingly, stockholders should not place undue reliance on this preliminary estimate. A copy of the Company's January 14, 2025, press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Report").

01

Item 7.01. Regulation FD Disclosure. The information set forth in Item 2.02 of this Report is incorporated into this Item 7.01 by reference. The Company will participate in the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, which is being held on Wednesday, January 15, 2024, at 7:30 a.m. Pacific Time, and has updated the corporate presentation that the Company intends to use at the conference. The Company may use this updated corporate presentation in meetings with investors from time to time as well. The Company's updated corporate presentation includes disclosure regarding the Company's estimated, preliminary and unaudited full-year revenue for fiscal year 2024, preliminary adjusted EBITDA and adjusted EBITDA margin for 2024, preliminary and unaudited 2024 gross margin percentage, preliminary and unaudited 2024 net income, its estimated cash, restricted cash and investments balance as of December 31, 2024, and additional financial and business updates. A copy of the Company's updated corporate presentation is attached hereto as Exhibit 99.2 and is hereby incorporated by reference. The preliminary financial data included in this Current Report on Form 8-K has been prepared by, and is the responsibility of, the Company's management. PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto. In accordance with General Instructions B.2 and B.6 of Form 8-K, the information included in Item 2.02 and Item 7.01 of this Report shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Ac

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated January 14, 2025, titled "Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets" 99.2 Vericel Corporation Presentation, dated January 14, 2025 104 * Cover Page Interactive Data File (embedded within the Inline XBRL) * Furnished herewith EXHIBIT INDEX Exhibit No. Description 99.1 Press Release, dated January 14, 2025, titled "Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets" 99.2 Vericel Corporation Presentation, dated January 14, 2025 104 * Cover Page Interactive Data File (embedded within the Inline XBRL) * Furnished herewith.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 , the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vericel Corporation Date: January 14, 2025 By: /s/ Sean C. Flynn Name: Sean C. Flynn Title: Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing